About Us

Our Board

Our Board of Directors are built to help guide our vision, bringing extensive experience in clinical drug development with a keen perspective on emerging technologies, next generation analytics and the application of precision medicine. Click to expand.

Edwina Baskin-Bey, MD

Edwina Baskin-Bey, MDEdwina S. Baskin-Bey, M.D. is an international biopharmaceutical veteran and award-winning physician scientist (IAOTP 2020) with more than 20-years’ experience in academia and industry. Dr. Baskin-Bey is the founder, owner, and president of The EGCC, a comprehensive global oncology consulting firm with representation in the US, UK, Germany, and The Netherlands. The EGCC offers direction and hands-on support to life science companies, venture, and investment banks with a focus of oncology product development. Concurrently, she is an Executive Board of Director to Fight Cancer Global, Houston, TX, a non-profit organization.

Previously, she was Chief Medical Officer and Executive Board Member at Nanobiotix, a Paris, France-based clinical-stage nanomedicine company pioneering new approaches for the treatment of cancer. Prior to, Dr. Baskin-Bey was Chief Medical Officer of Innocrin Pharmaceuticals, a biotech focused on androgen biosynthesis inhibition for the treatment of solid tumors, where she led the development and implementation of the clinical and corporate strategy. Dr. Baskin-Bey joined Innocrin from Janssen Oncology (Johnson & Johnson), where she steered both early- and late-stage oncology global development programs for newly in-licensed products. Precursory to, whilst based in the EU, she was responsible for life cycle management of several large global oncology programs as well as Head of European Medical Affairs for Astellas Pharma.

Dr. Baskin-Bey received a bachelor’s degree in Chemistry from Hunter College, NY, NY, and a medical degree from Mount Sinai/NYU School of Medicine, NY, NY. She was trained in- general surgery and oncology at The Mayo Clinic, Rochester, MN; in clinical trial biostatistics from EORTC, Brussels, BE; in business leadership from INSEAD, Fontainebleau, FR; and in basic science research principles by the National Institutes of Health in Bethesda, MD.

Vern Davenport

Vern DavenportVern Davenport is Partner at NovaQuest Capital Management and has more than 35 years experience of building and transforming healthcare technology and services companies. He is Investment Committee Member at NovaQuest Private Equity.

Before NovaQuest, Vern was CEO and Board Member at Medfusion. Previously, Vern was Chairman and CEO of Medquist before and after the privatization of the company. He rebranded the company to M*Modal and led the take private process, resulting in the sale to One Equity Partners.

Vern’s experience includes President, Allscripts; CEO, Misys Healthcare; GM & EVP, Kodak Health Group (now Carestream Health) and executive leadership roles at Siemens and Shared Medical Systems. He also was at IBM for 11 years, serving in sales leadership and executive management positions. 

Vern received an MBA and a BSBA in Business from East Carolina University.  He serves on the East Carolina Board of Trustees and the WakeMed Health and Hospitals Boards and has held other board positions.

Nick Dyer

Nick DyerNick Dyer is the CEO of Catalyst Clinical Research, LLC and has more than 21 years experience in healthcare and life sciences.  Previously, Nick was President of Novella Clinical and also served as Chief Commercial Officer.  At Novella, Nick fervently embraced the need for therapeutically-focused CRO solutions interlaced with a flexible, small biotech, customer service model.  Nick also led clinical operations, finance, IT, and sales/marketing functions for Quintiles (IQVIA) and Pharmaceutical Product Development.  Previously, Nick led a finance group for a large UK based hospital following a three-year postgraduate healthcare management program with the UK National Health Service.

Nick received a First Class Bachelor’s Degree in Economics from the University of Greenwich, London and qualified as a Chartered Public Finance Accountant in 1995.

David A. Dworaczyk, PhD

David DworaczykDr. Dworaczyk is a highly experienced senior executive who has done extensive work with Healthcare, Pharma, Biotech, Healthcare, Informatics, Diagnostic and CRO companies as well as life and health science focused Venture and Private Equity investment groups assessing and evaluating investment opportunities from an operational, strategic and business potential perspective.  He is currently CEO at Bryn Pharma, an early stage pharma company focusing on immunology, allergy and anaphylaxis.  Prior to joining Bryn, he directed the Life and Health Sciences Strategic Development effort at Oracle and has also served as COO for Comprehensive Clinical Development, Sr. Vice President, General Manager & COO at Generation Health/MetaDiagnostic, a start-up focused on molecular diagnostics, genomics and personalized medicine, was COO for The Moffitt Cancer Center/M2Gen (for-profit subsidiary), was CEO of a mid-size international CRO,SRA International and Sr. VP of North American operations at Quintiles.  He has had global responsibilities including leading all operational functions across multiple business units, genomics/biomarkers, translational research, patient targeted drug development, gene based trial matching, translational research, precision/personalized medicine, healthcare analytics/informatics, population health as well as the integration and effective use of Real World Data/Evidence and “Big/Complex” data.

Dr. Dworaczyk has over 40-yrs of experience in the pharmaceutical, biotechnology, molecular diagnostic, medical device and CRO industry where he has held senior level positions in R&D, Global Operations, Business Development (L&A/M&A), Clinical Development, Strategic Planning, Project Management, Commercial Operations and healthcare analytics.  He has been directly engaged in start-up companies and turn-around situations.   He has also gained expertise in Decision and Risk Analysis, has done extensive research in strategic planning, R&D portfolio management

Dr. Dworaczyk has advanced degrees in Cell and Molecular Biology and in Leadership and Business Administration.


Jeffrey Kasher, PhD

Jeff Kasher, PhDDr. Jeff Kasher is a pharmaceutical development executive with more than 30 years of experience. He focused on improving clinical outcomes, bringing patients and research sites into the drug development process, and decreasing time to market.  He is a top 20 Innovators Changing the Face of the Clinical Trials Industry and was recognized on The Medicine Maker Power List 2015.

Jeff spent 28 years at Eli Lilly and Company serving in various leadership positions, including VP of Clinical Innovation and Implementation and VP and Chief Operation Officer of the Global Clinical Development Organization. 

Jeff was a Post Doctoral Fellow at the Yale University School of Medicine and received a PhD, Pharmacology from the State University of New York Upstate Medical University. He received a BS in Chemistry from Franklin & Marshall College. Jeff currently serves as Board Director of Javara Research, an integrated research organization, and is President of Patients Can’t Wait LLC.

Jeff Edwards

Jeff Edwards has over 18 years of investment experience and is a Partner at NovaQuest Capital Management. He is responsible for transaction origination, investment policy, fundraising, and the day-to-day management of NovaQuest Capital Management. In addition, he directs the Private Equity team in acquisitions, divestitures, and oversight of portfolio companies.

Prior to joining NovaQuest, Jeff co-led the Principal Investment Private Equity program at the Teacher Retirement System of Texas, leading the efforts in the Healthcare and Industrial sectors across a variety of geographies. In that role, he was responsible for making investment decisions, deal origination, as well as portfolio construction and portfolio management.

Jeff’s previous experience also includes M&A advisory work for Raymond James Capital Markets, focusing on middle-market companies. He also worked for State Street Global Markets (SSGM). His efforts were focused on private equity fund formation, portfolio management, and investment due diligence. Before moving back to the capital markets sector, Jeff worked in finance and administrative roles in the healthcare industry with Carolinas HealthCare Systems and HCA, Inc. He started his career with the middle market investment bank RW Baird.

Jeff received an MBA from the University of North Carolina at Chapel Hill, an MSF from Boston College, and a BA from the University of Tennessee at Knoxville. He is also a CAIA Charter Holder.


Amelia Wall Warner, PharmD, RPH

Amelia Wall WarnerAmelia Wall Warner has more than 20 years of healthcare and management experience.  Currently, Amelia is the Founder and CEO of Clinical Trial Concepts, Inc., specializing in SaaS for the pharmaceutical industry. 

She also founded Global Specimen Solutions, Inc, an innovative specimen management CRO and Informatics Company, and sold the company to LabCorp in December 2017.  Previously, Amelia served as Head of Clinical Pharmacogenomics/ Clinical Specimen Management for Merck and Head of Pharmacogenomics for the Children’s Hospital of Philadelphia. 

Amelia is also the former CEO and President of Gentris Corporation, successfully leading the operational and financial turnaround of the company that resulted in the acquisition by Cancer Genetics, Inc. 

Amelia received her doctorate from University of North Carolina and completed residency and fellowship training at St Jude Children’s Research Hospital.  She has held numerous leadership roles and won industry awards including invited PhRMA representative to ICH E16 and Chair (selected by her peers), Industry Pharmacogenomics Working Group.